NCI-H1734Homo sapiens (Human)Cancer cell line

Also known as: NCIH1734, H-1734, H1734, NCI-H734

🤖 AI SummaryBased on 13 publications

Quick Overview

Human lung cancer cell line with known mutations and drug sensitivity profiles.

Detailed Summary

The NCI-H1734 cell line is a human lung cancer cell line derived from a small cell lung cancer (SCLC) tumor. It is widely used in cancer research for studying the molecular mechanisms of SCLC and for drug development. This cell line has been characterized for its genetic mutations, including alterations in the RB1 and TP53 genes, which are commonly associated with SCLC. Research on NCI-H1734 has contributed to understanding the role of these mutations in cancer progression and therapeutic response. The cell line is also utilized in studies involving proteomic and transcriptomic profiling to identify potential therapeutic targets and biomarkers for SCLC.

Research Applications

Molecular mechanisms of SCLCDrug developmentGenetic mutation analysisProteomic and transcriptomic profiling

Key Characteristics

RB1 and TP53 mutationsSCLC originUsed in drug sensitivity studies
Generated on 6/17/2025

Basic Information

Database IDCVCL_1491
SpeciesHomo sapiens (Human)
Tissue SourceLung[UBERON:UBERON_0002048]

Donor Information

Age56
Age CategoryAdult
SexFemale

Disease Information

DiseaseLung adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeATCC
Source IDACH-000675_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg273Leu (c.818G>T)HomozygousSomatic mutation acquired during proliferationPubMed=31541927, PubMed=23613873, PubMed=15735012
MutationSimpleRB1p.Ser127Ile (c.380G>T)Homozygous-Unknown, Unknown
MutationSimpleKRASp.Gly13Cys (c.37G>T)Heterozygous-Unknown, Unknown, PubMed=28273451, PubMed=25230021, PubMed=24224046, PubMed=22705003
MutationSimpleATMp.Gln65Pro (c.194A>C)Heterozygous-Unknown, Unknown, PubMed=27602502

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
13
D13S317
11,12
D16S539
12
D18S51
13,15
D19S433
14,15
D21S11
33.2
D2S1338
18,23
D3S1358
16
D5S818
10
D7S820
10,11
D8S1179
13
FGA
24
Penta D
11
Penta E
12,14
TH01
7,9.3
TPOX
11
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.

Maughan T.S., Ryan A.J.

Oncotarget 7:60807-60822(2016).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.

Nat. Commun. 4:2617.1-2617.13(2013).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).